PROMETHEUS BIOSCIENCES, INC. Operating Cash Flow
PROMETHEUS BIOSCIENCES, INC. reported Operating Cash Flow of -$39.54 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-09.
Discontinued › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2023-05-09
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2023-03-31 was -$39.54M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2022-12-31 was -$41.12M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2022-09-30 was -$23.90M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2022-06-30 was -$28.85M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$123.25M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2021 was -$63.51M.
- PROMETHEUS BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2020 was -$28.02M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2023-03-31 | -$39.54M 10-Q · filed 2023-05-09 | -$80.67M derived: sum of 2 quarters · filed 2023-05-09 | -$104.56M derived: sum of 3 quarters · filed 2023-05-09 | -$133.41M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | -$41.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$65.02M derived: sum of 2 quarters · filed 2023-02-28 | -$93.87M derived: sum of 3 quarters · filed 2023-02-28 | -$123.25M 10-K · filed 2023-02-28 |
| 2022-09-30 | -$23.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$52.74M derived: sum of 2 quarters · filed 2022-11-09 | -$82.13M 10-Q · filed 2022-11-09 | -$104.31M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-06-30 | -$28.85M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$58.23M 10-Q · filed 2022-08-11 | -$80.41M derived: sum of 3 quarters · filed 2023-05-09 | -$97.39M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-03-31 | -$29.39M 10-Q · filed 2023-05-09 | -$51.56M derived: sum of 2 quarters · filed 2023-05-09 | -$68.54M derived: sum of 3 quarters · filed 2023-05-09 | -$73.90M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$22.18M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$39.15M derived: sum of 2 quarters · filed 2023-02-28 | -$44.51M derived: sum of 3 quarters · filed 2023-02-28 | -$63.51M 10-K · filed 2023-02-28 |
| 2021-09-30 | -$16.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$22.33M derived: sum of 2 quarters · filed 2022-11-09 | -$41.33M 10-Q · filed 2022-11-09 | -$46.65M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$5.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$24.35M 10-Q · filed 2022-08-11 | -$29.67M derived: sum of 3 quarters · filed 2023-02-28 | -$34.21M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$18.99M 10-Q · filed 2022-05-12 | -$24.31M derived: sum of 2 quarters · filed 2023-02-28 | -$28.85M derived: sum of 3 quarters · filed 2023-02-28 | -$41.75M derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | -$5.32M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$9.86M derived: sum of 2 quarters · filed 2023-02-28 | -$22.76M derived: sum of 3 quarters · filed 2023-02-28 | -$28.02M 10-K · filed 2023-02-28 |
| 2020-09-30 | -$4.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$17.44M derived: sum of 2 quarters · filed 2021-11-12 | -$22.70M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | -$12.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$18.16M 10-Q · filed 2021-08-11 | ||
| 2020-03-31 | -$5.26M 10-Q · filed 2021-05-13 |